Navigation Links
Bronchial Thermoplasty: Boon to Severe Asthma Patients?

Encouraging results for the use of bronchial thermoplasty procedure were reported by the Research in Severe Asthma (RISA) Trial , at the annual scientific assembly of the American Thoracic Society (ATS) by Neil Thomson,MD, Professor of Respiratory Medicine, University of Glasgow, Scotland. This announcement came from Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma.

Severe asthma patients who underwent bronchial thermoplasty showed significant improvements in asthma control, pulmonary function and quality of life. There was also lesser use of rescue medications. The novel, non-drug procedure is under clinical investigation in the United States.

The RISA Trial was conducted at a total of eight hospitals, in three countries, and evaluated the safety and efficacy of bronchial thermoplasty in 32 adult subjects with severe persistent asthma who remained symptomatic despite taking regular asthma medications.

Compared to patients who received only standard asthma medications, patients who received the bronchial thermoplasty procedure and standard medications showed clinically and statistically significant improvements in pulmonary function, quality of life, and asthma control, and used less rescue medication nearly 6 months following the procedure.

One year following the treatment, 50% of bronchial thermoplasty treated patients were able to wean completely off oral corticosteroids (OCS), compared to 14% of patients who did not receive the treatment. Further, a greater overall reduction in OCS dose was observed at 52 weeks in the bronchial thermoplasty treated patients compared with those that did not receive treatment at 52 weeks, although this difference didnt reach statistical significance. The study was not powered to show statistical significance in medication changes.

In this group of patients with severe asthma, an increase in respi ratory-related symptoms, and hospitalizations related to these symptoms, were expected and observed during the period immediately following the procedure. These symptoms were of the type expected following bronchoscopy in patients with asthma, and they resolved on average within seven days.

"Following bronchial thermoplasty, patients with severe, refractory asthma demonstrated significant improvements in pulmonary function and asthma control," states Dr. Thomson. "These significant and seemingly long-lasting improvements came at the cost of a short-term increase in hospitalizations, but the apparent benefits seem to be greater than the manageable consequences of the procedure."

"The results from this randomized, controlled, multi-center trial provide some hope for patients with severe, refractory asthma people who despite taking state-of-the-art medications are still experiencing the disruptive and distressing symptoms of their asthma," states Glen French, CEO of Asthmatx, Inc. "We were particularly encouraged by the data that suggested that patients may be able to reduce their oral steroid dose and still maintain their asthma control."


'"/>




Related medicine news :

1. New Drug for Bronchial Asthma
2. Bronchial thermoplasty – a promising treatment for asthmatic
3. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
4. Severe stress weakens immunity
5. Severe Acute respiratory Syndrome (SARS)
6. WHO Travel Advice to prevent spread of "Severe Acute Respiratory Syndrome (SARS)
7. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
8. Severe sleep apnea can cause liver problems
9. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
10. Strong Magnetic Stimulation Can Help Treating Severe Depression
11. Patients Suffering From Severe Mental Diseases Are At Risk Of Being Crime Victims
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's ... goals for each and every seminar, session and class she offers. At ... brainwave tools which help energize creativity, focus mental functions, enhance athletic focus and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... named a finalist in the 8th Annual DecisionHealth Platinum Awards in recognition of ... Qualis Health’s work is recognized across multiple award categories, highlighting four of the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting ... on all facets of clinical trial planning and management. Pharmica discussed the importance ... more. In addition, attendees stopping by Pharmica’s booth were able to demo its ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
(Date:2/16/2017)... REDWOOD CITY, Calif. , Feb. 16, 2017 ... ), a specialty pharmaceutical company focused on the ... treatment of moderate-to-severe acute pain, announced that ... executive officer and a member of the company,s ... Mr. Angotti brings over two decades of experience ...
(Date:2/16/2017)... 16, 2017 Research and Markets has announced ... Analysis & Trends - Function, Application, Cancer Type, Technology - Forecast ... ... Market is poised to grow at a CAGR of around 28.6% ... Some of the prominent trends that the ...
Breaking Medicine Technology: